Contrast enhancing pattern on pre-treatment MRI predicts response to anti-angiogenic treatment in recurrent glioblastoma: comparison of bevacizumab and temozolomide treatment

MLA

Hye Hyeon Moon, et al. “Contrast Enhancing Pattern on Pre-Treatment MRI Predicts Response to Anti-Angiogenic Treatment in Recurrent Glioblastoma: Comparison of Bevacizumab and Temozolomide Treatment.” Journal of Neuro-Oncology, vol. 157, no. 3, Jan. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....ce86b8f45689be7748c56441ee3b8182&authtype=sso&custid=ns315887.

APA

Hye Hyeon Moon, Ji Eun Park, Young-Hoon Kim, Jeong Hoon Kim, & Ho Sung Kim. (2022). Contrast enhancing pattern on pre-treatment MRI predicts response to anti-angiogenic treatment in recurrent glioblastoma: comparison of bevacizumab and temozolomide treatment. Journal of Neuro-Oncology, 157(3).

Chicago

Hye Hyeon Moon, Ji Eun Park, Young-Hoon Kim, Jeong Hoon Kim, and Ho Sung Kim. 2022. “Contrast Enhancing Pattern on Pre-Treatment MRI Predicts Response to Anti-Angiogenic Treatment in Recurrent Glioblastoma: Comparison of Bevacizumab and Temozolomide Treatment.” Journal of Neuro-Oncology 157 (3). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....ce86b8f45689be7748c56441ee3b8182&authtype=sso&custid=ns315887.